First, the limited number of studies investigating the prognostic impact of the PTGS2 (COX-2) gene expression in marker-expressing colorectal cancers (CRCs) made it challenging to compare our findings with existing literature. This evidence concerns the gene PTGS2 and colorectal cancer.